Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication.

Alhenc-Gelas F, Bouby N, Girolami JP.

Front Med (Lausanne). 2019 Jun 27;6:136. doi: 10.3389/fmed.2019.00136. eCollection 2019. Review.

2.

A New Player in Circulatory Adaptation to Orthostatism: Better to Play With Than Without Him.

Alhenc-Gelas F.

Circ Res. 2018 Mar 16;122(6):802-803. doi: 10.1161/CIRCRESAHA.118.312749. No abstract available.

PMID:
29700080
3.

Is Plasma Renin Activity Genetically Determined and How Much Does It Matter for Treating Hypertension?

Alhenc-Gelas F, Menard J.

Circ Genom Precis Med. 2018 Apr;11(4):e002139. doi: 10.1161/CIRCGEN.118.002139. No abstract available.

PMID:
29650769
4.

Genetically increased angiotensin I-converting enzyme alters peripheral and renal vascular reactivity to angiotensin II and bradykinin in mice.

Chollet C, Placier S, Chatziantoniou C, Hus-Citharel A, Caron N, Roussel R, Alhenc-Gelas F, Bouby N.

Am J Physiol Heart Circ Physiol. 2018 Feb 1;314(2):H350-H358. doi: 10.1152/ajpheart.00356.2017. Epub 2017 Nov 3.

5.

Neuroprotective effect of kinin B1 receptor activation in acute cerebral ischemia in diabetic mice.

Desposito D, Zadigue G, Taveau C, Adam C, Alhenc-Gelas F, Bouby N, Roussel R.

Sci Rep. 2017 Aug 25;7(1):9410. doi: 10.1038/s41598-017-09721-0.

6.

Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes.

El Boustany R, Taveau C, Chollet C, Velho G, Bankir L, Alhenc-Gelas F, Roussel R, Bouby N.

J Diabetes Complications. 2017 Jun;31(6):929-932. doi: 10.1016/j.jdiacomp.2017.04.005. Epub 2017 Apr 6.

PMID:
28412033
7.

Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implications.

Desposito D, Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Biol Chem. 2016 Dec 1;397(12):1217-1222. doi: 10.1515/hsz-2016-0228. Review.

PMID:
27622831
8.

Take a deep breath and check your heart.

Alhenc-Gelas F.

J Diabetes Complications. 2016 Jul;30(5):758-9. doi: 10.1016/j.jdiacomp.2016.03.002. Epub 2016 Mar 5. No abstract available.

PMID:
27020537
9.

Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade.

Desposito D, Chollet C, Taveau C, Descamps V, Alhenc-Gelas F, Roussel R, Bouby N, Waeckel L.

Clin Sci (Lond). 2016 Jan;130(1):45-56. doi: 10.1042/CS20150295. Epub 2015 Oct 6.

PMID:
26443866
10.

Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes.

Velho G, Ragot S, Mohammedi K, Gand E, Fraty M, Fumeron F, Saulnier PJ, Bellili-Munoz N, Bouby N, Potier L, Alhenc-Gelas F, Marre M, Hadjadj S, Roussel R.

Diabetes. 2015 Sep;64(9):3262-72. doi: 10.2337/db14-1852. Epub 2015 May 6.

11.

Tissue kallikrein is required for the cardioprotective effect of cyclosporin A in myocardial ischemia in the mouse.

Youcef G, Belaidi E, Waeckel L, Fazal L, Clemessy M, Vincent MP, Zadigue G, Richer C, Alhenc-Gelas F, Ovize M, Pizard A.

Biochem Pharmacol. 2015 Mar 1;94(1):22-9. doi: 10.1016/j.bcp.2015.01.007. Epub 2015 Jan 23.

PMID:
25623731
12.

Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice.

Desposito D, Potier L, Chollet C, Gobeil F Jr, Roussel R, Alhenc-Gelas F, Bouby N, Waeckel L.

J Pharmacol Exp Ther. 2015 Feb;352(2):218-26. doi: 10.1124/jpet.114.219196. Epub 2014 Nov 14.

PMID:
25398240
13.

Genetic manipulation and genetic variation of the kallikrein-kinin system: impact on cardiovascular and renal diseases.

Girolami JP, Blaes N, Bouby N, Alhenc-Gelas F.

Prog Drug Res. 2014;69:145-96. Review.

PMID:
25130042
14.

Tissue kallikrein deficiency, insulin resistance, and diabetes in mouse and man.

Potier L, Waeckel L, Fumeron F, Bodin S, Fysekidis M, Chollet C, Bellili N, Bonnet F, Gusto G, Velho G, Marre M, Alhenc-Gelas F, Roussel R, Bouby N; DESIR Study Group.

J Endocrinol. 2014 Apr 22;221(2):297-308. doi: 10.1530/JOE-13-0529. Print 2014 May.

PMID:
24599937
15.

Cardioprotective effect of VEGF and venom VEGF-like protein in acute myocardial ischemia in mice: effect on mitochondrial function.

Messadi E, Aloui Z, Belaidi E, Vincent MP, Couture-Lepetit E, Waeckel L, Decorps J, Bouby N, Gasmi A, Karoui H, Ovize M, Alhenc-Gelas F, Richer C.

J Cardiovasc Pharmacol. 2014 Mar;63(3):274-81. doi: 10.1097/FJC.0000000000000045.

PMID:
24220315
16.

Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.

Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R.

Diabetes Care. 2013 Nov;36(11):3639-45. doi: 10.2337/dc13-0683. Epub 2013 Jul 17.

17.

Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes.

Potier L, Waeckel L, Vincent MP, Chollet C, Gobeil F Jr, Marre M, Bruneval P, Richer C, Roussel R, Alhenc-Gelas F, Bouby N.

J Pharmacol Exp Ther. 2013 Jul;346(1):23-30. doi: 10.1124/jpet.113.203927. Epub 2013 Apr 16.

PMID:
23591995
18.

Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man.

Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Thromb Haemost. 2013 Sep;110(3):476-83. doi: 10.1160/TH12-12-0937. Epub 2013 Apr 4. Review.

PMID:
23572029
19.

Highlight: kinin 2012 in Paris.

Girolami JP, Alhenc-Gelas F.

Biol Chem. 2013 Mar;394(3):317. doi: 10.1515/hsz-2013-0122. No abstract available.

PMID:
23382310
20.

Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.

Potier L, Waeckel L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Biol Chem. 2013 Mar;394(3):329-33. doi: 10.1515/hsz-2012-0332. Review.

PMID:
23324381
21.

New susceptibility loci associated with kidney disease in type 1 diabetes.

Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ, Williams WW, Sadlier DM, Mäkinen VP, Swan EJ, Palmer C, Boright AP, Ahlqvist E, Deshmukh HA, Keller BJ, Huang H, Ahola AJ, Fagerholm E, Gordin D, Harjutsalo V, He B, Heikkilä O, Hietala K, Kytö J, Lahermo P, Lehto M, Lithovius R, Osterholm AM, Parkkonen M, Pitkäniemi J, Rosengård-Bärlund M, Saraheimo M, Sarti C, Söderlund J, Soro-Paavonen A, Syreeni A, Thorn LM, Tikkanen H, Tolonen N, Tryggvason K, Tuomilehto J, Wadén J, Gill GV, Prior S, Guiducci C, Mirel DB, Taylor A, Hosseini SM; DCCT/EDIC Research Group, Parving HH, Rossing P, Tarnow L, Ladenvall C, Alhenc-Gelas F, Lefebvre P, Rigalleau V, Roussel R, Tregouet DA, Maestroni A, Maestroni S, Falhammar H, Gu T, Möllsten A, Cimponeriu D, Ioana M, Mota M, Mota E, Serafinceanu C, Stavarachi M, Hanson RL, Nelson RG, Kretzler M, Colhoun HM, Panduru NM, Gu HF, Brismar K, Zerbini G, Hadjadj S, Marre M, Groop L, Lajer M, Bull SB, Waggott D, Paterson AD, Savage DA, Bain SC, Martin F, Hirschhorn JN, Godson C, Florez JC, Groop PH, Maxwell AP.

PLoS Genet. 2012 Sep;8(9):e1002921. doi: 10.1371/journal.pgen.1002921. Epub 2012 Sep 20.

22.

Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse.

Waeckel L, Potier L, Chollet C, Taveau C, Bruneval P, Roussel R, Alhenc-Gelas F, Bouby N.

Endocrinology. 2012 Aug;153(8):3886-96. doi: 10.1210/en.2012-1225. Epub 2012 Jun 5.

PMID:
22669897
23.

Low water intake and risk for new-onset hyperglycemia.

Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L; D.E.S.I.R. Study Group.

Diabetes Care. 2011 Dec;34(12):2551-4. doi: 10.2337/dc11-0652. Epub 2011 Oct 12.

24.

Kinins as therapeutic agents in cardiovascular and renal diseases.

Alhenc-Gelas F, Bouby N, Richer C, Potier L, Roussel R, Marre M.

Curr Pharm Des. 2011;17(25):2654-62. Review.

PMID:
21728987
25.

Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity.

Metzger R, Franke FE, Bohle RM, Alhenc-Gelas F, Danilov SM.

Microvasc Res. 2011 Mar;81(2):206-15. doi: 10.1016/j.mvr.2010.12.003. Epub 2010 Dec 16.

PMID:
21167844
26.

Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells.

Spinetti G, Fortunato O, Cordella D, Portararo P, Kränkel N, Katare R, Sala-Newby GB, Richer C, Vincent MP, Alhenc-Gelas F, Tonolo G, Cherchi S, Emanueli C, Madeddu P.

Circ Res. 2011 Feb 4;108(3):284-93. doi: 10.1161/CIRCRESAHA.110.236786. Epub 2010 Dec 16.

27.

Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.

Messadi E, Vincent MP, Griol-Charhbili V, Mandet C, Colucci J, Krege JH, Bruneval P, Bouby N, Smithies O, Alhenc-Gelas F, Richer C.

FASEB J. 2010 Dec;24(12):4691-700. doi: 10.1096/fj.10-165902. Epub 2010 Jul 28.

28.

Association of common variants in NPPA and NPPB with blood pressure does not translate into kidney damage in a general population study.

Maimaitiming S, Roussel R, Hadjadj S, Fumeron F, Aubert R, Emery N, Velho G, Mohammedi K, Travert F, Tichet J, Alhenc-Gelas F, Balkau B, Marre M; D.E.S.I.R. Study Group.

J Hypertens. 2010 Jun;28(6):1230-3. doi: 10.1097/HJH.0b013e328338a901.

PMID:
20407391
29.

Kallikrein protects against microalbuminuria in experimental type I diabetes.

Bodin S, Chollet C, Goncalves-Mendes N, Gardes J, Pean F, Heudes D, Bruneval P, Marre M, Alhenc-Gelas F, Bouby N.

Kidney Int. 2009 Aug;76(4):395-403. doi: 10.1038/ki.2009.208. Epub 2009 Jun 10.

30.

Tissue kallikrein deficiency and renovascular hypertension in the mouse.

Griol-Charhbili V, Sabbah L, Colucci J, Vincent MP, Baudrie V, Laude D, Elghozi JL, Bruneval P, Picard N, Meneton P, Alhenc-Gelas F, Richer C.

Am J Physiol Regul Integr Comp Physiol. 2009 May;296(5):R1385-91. doi: 10.1152/ajpregu.90411.2008. Epub 2009 Feb 25.

31.

Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization.

Stone OA, Richer C, Emanueli C, van Weel V, Quax PH, Katare R, Kraenkel N, Campagnolo P, Barcelos LS, Siragusa M, Sala-Newby GB, Baldessari D, Mione M, Vincent MP, Benest AV, Al Haj Zen A, Gonzalez J, Bates DO, Alhenc-Gelas F, Madeddu P.

Arterioscler Thromb Vasc Biol. 2009 May;29(5):657-64. doi: 10.1161/ATVBAHA.108.182139. Epub 2009 Jan 22.

32.

Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney.

Pizard A, Richer C, Bouby N, Picard N, Meneton P, Azizi M, Alhenc-Gelas F.

Biol Chem. 2008 Jun;389(6):701-6. doi: 10.1515/BC.2008.081. Review.

33.

Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies.

Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, Travert F, Abi Khalil C, Miot A, Alhenc-Gelas F, Lievre M, Marre M; DIABHYCAR Study Group; DIAB2NEPHROGENE Study Group; SURDIAGENE Study Group.

Diabetes Care. 2008 Sep;31(9):1847-52. doi: 10.2337/dc07-2079. Epub 2008 Jun 3.

34.

Aspirin inhibits human bradykinin B2 receptor ligand binding function.

Gardes J, Michineau S, Pizard A, Alhenc-Gelas F, Rajerison RM.

Biochem Pharmacol. 2008 May 1;75(9):1807-16. doi: 10.1016/j.bcp.2008.02.001. Epub 2008 Feb 12.

PMID:
18355801
35.

Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice.

Pons S, Griol-Charhbili V, Heymes C, Fornes P, Heudes D, Hagege A, Loyer X, Meneton P, Giudicelli JF, Samuel JL, Alhenc-Gelas F, Richer C.

Eur J Heart Fail. 2008 Apr;10(4):343-51. doi: 10.1016/j.ejheart.2008.02.002. Epub 2008 Mar 14.

36.

Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins exretion in man.

Azizi M, Emanueli C, Peyrard S, Maddedu P, Alhenc-Gelas F, Campbell DJ.

J Hypertens. 2008 Apr;26(4):714-20. doi: 10.1097/HJH.0b013e3282f4d1fa.

PMID:
18327081
37.

Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice.

Messadi-Laribi E, Griol-Charhbili V, Gaies E, Vincent MP, Heudes D, Meneton P, Alhenc-Gelas F, Richer C.

Clin Exp Pharmacol Physiol. 2008 Apr;35(4):489-93. doi: 10.1111/j.1440-1681.2008.04902.x. Review.

PMID:
18307747
38.

Endothelial function and chronic exposure to air pollution in normal male subjects.

Briet M, Collin C, Laurent S, Tan A, Azizi M, Agharazii M, Jeunemaitre X, Alhenc-Gelas F, Boutouyrie P.

Hypertension. 2007 Nov;50(5):970-6. Epub 2007 Sep 17.

PMID:
17875820
39.

Partial human genetic deficiency in tissue kallikrein activity and renal calcium handling.

Blanchard A, Azizi M, Peyrard S, Stern N, Alhenc-Gelas F, Houillier P, Jeunemaitre X.

Clin J Am Soc Nephrol. 2007 Mar;2(2):320-5. Epub 2007 Jan 3.

40.

Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.

Messadi-Laribi E, Griol-Charhbili V, Pizard A, Vincent MP, Heudes D, Meneton P, Alhenc-Gelas F, Richer C.

J Pharmacol Exp Ther. 2007 Oct;323(1):210-6. Epub 2007 Jul 16.

PMID:
17636004
41.

Murine models of myocardial and limb ischemia: diagnostic end-points and relevance to clinical problems.

Madeddu P, Emanueli C, Spillmann F, Meloni M, Bouby N, Richer C, Alhenc-Gelas F, Van Weel V, Eefting D, Quax PH, Hu Y, Xu Q, Hemdahl AL, van Golde J, Huijberts M, de Lussanet Q, Struijker Boudier H, Couffinhal T, Duplaa C, Chimenti S, Staszewsky L, Latini R, Baumans V, Levy BI.

Vascul Pharmacol. 2006 Nov;45(5):281-301. Epub 2006 Aug 22. Review.

PMID:
17010676
42.

A second expressed kininogen gene in mice.

Shesely EG, Hu CB, Alhenc-Gelas F, Meneton P, Carretero OA.

Physiol Genomics. 2006 Jul 12;26(2):152-7.

PMID:
16837654
43.

Human bradykinin B2 receptor sialylation and N-glycosylation participate with disulfide bonding in surface receptor dimerization.

Michineau S, Alhenc-Gelas F, Rajerison RM.

Biochemistry. 2006 Feb 28;45(8):2699-707.

PMID:
16489763
44.

Angiotensin-converting enzyme (ACE) dimerization is the initial step in the ACE inhibitor-induced ACE signaling cascade in endothelial cells.

Kohlstedt K, Gershome C, Friedrich M, Müller-Esterl W, Alhenc-Gelas F, Busse R, Fleming I.

Mol Pharmacol. 2006 May;69(5):1725-32. Epub 2006 Feb 13.

PMID:
16476786
45.

Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption.

Picard N, Van Abel M, Campone C, Seiler M, Bloch-Faure M, Hoenderop JG, Loffing J, Meneton P, Bindels RJ, Paillard M, Alhenc-Gelas F, Houillier P.

J Am Soc Nephrol. 2005 Dec;16(12):3602-10. Epub 2005 Oct 26.

46.

[Gene transfers of kallikrein, bradykinin receptor B2 and a mutated B2 receptor stimulate neoangiogenesis in peripheral ischemia].

Griffon C, Boehm N, Allegrini J, Miternique A, Alhenc-Gelas F, Hudlett P, Stephan D.

Arch Mal Coeur Vaiss. 2005 Jul-Aug;98(7-8):825-9. French.

PMID:
16220755
47.

Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.

Weekers L, Bouhanick B, Hadjadj S, Gallois Y, Roussel R, Pean F, Ankotche A, Chatellier G, Alhenc-Gelas F, Lefebvre PJ, Marre M.

Diabetes. 2005 Oct;54(10):2961-7.

48.

[Polymorphism of kallikrein gene and abnormalities of the endothelial function].

Azizi M, Boutouyrie P, Alhenc-Gelas F, Laurent S, Jeunemaitre X.

Med Sci (Paris). 2005 Jun-Jul;21(6-7):584-5. French. No abstract available.

49.

Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.

Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, Alhenc-Gelas F, Richer C.

FASEB J. 2005 Jul;19(9):1172-4. Epub 2005 Apr 28.

PMID:
15860541
50.

Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans.

Azizi M, Boutouyrie P, Bissery A, Agharazii M, Verbeke F, Stern N, Bura-Rivière A, Laurent S, Alhenc-Gelas F, Jeunemaitre X.

J Clin Invest. 2005 Mar;115(3):780-7.

Supplemental Content

Loading ...
Support Center